Suppression of tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis

Oncogene

Volumn 31, Issue 32, 2012, Pages 3679-3695

  Kosa, P ^a   Szabo, R ^a   Molinolo, A A ^a   Bugge, T H ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

colon carcinogenesis; inflammatory bowel disease; intestinal barrier

Indexed keywords

MATRIPTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC INFLAMMATION; COLITIS; COLON ADENOCARCINOMA; COLON CARCINOGENESIS; COMMENSAL; CONTROLLED STUDY; FEMALE; INTESTINE EPITHELIUM; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; MALE; MOUSE; NONHUMAN; PENETRANCE; PRIORITY JOURNAL; SUPPRESSION OF TUMORIGENICITY 14 GENE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADENOMA; ANIMALS; ANTI-BACTERIAL AGENTS; BASEMENT MEMBRANE; BETA CATENIN; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLITIS; COLON; COLONIC NEOPLASMS; EPITHELIUM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL ABSORPTION; METAGENOME; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION;

MUS;

EID: 84864930264     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.545     Document Type: Article

References (75)

1. Acuff HB, Sinnamon M, Fingleton B, Boone B, Levy SE, Chen X et al. (2006). Analysis of host-and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res 66: 7968-7975.
2. Andreasen PA, Egelund R, Petersen HH. (2000). The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57: 25-40.
3. Balbin M, Fueyo A, Tester AM, Pendas AM, Pitiot AS, Astudillo A et al. (2003). Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 35: 252-257.
4. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G et al. (1996). Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 98: 1010-1020.
5. Bhatt AS, Welm A, Farady CJ, Vasquez M, Wilson K, Craik CS. (2007). Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc Natl Acad Sci USA 104: 5771-5776.
6. Borgono CA, Diamandis EP. (2004). The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 4: 876-890.
7. Bugge TH, Antalis TM, Wu Q. (2009). Type II transmembrane serine proteases. J Biol Chem 284: 23177-23181.
8. Buzza MS, Netzel-Arnett S, Shea-Donohue T, Zhao A, Lin CY, List K et al. (2010). Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine. Proc Natl Acad Sci USA 107: 4200-4205.
9. Cheng H, Fukushima T, Takahashi N, Tanaka H, Kataoka H. (2009). Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cancer Res 69: 1828-1835.
10. Danese S, Mantovani A. (2010). Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene 29: 3313-3323.
11. de Lau W, Barker N, Clevers H. (2007). WNT signaling in the normal intestine and colorectal cancer. Front Biosci 12: 471-491.
12. Deng L, Zhou JF, Sellers RS, Li JF, Nguyen AV, Wang Y et al. (2010). A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am J Pathol 176: 952-967.
13. Engle SJ, Ormsby I, Pawlowski S, Boivin GP, Croft J, Balish E et al. (2002). Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res 62: 6362-6366.
14. Erdman SE, Poutahidis T, Tomczak M, Rogers AB, Cormier K, Plank B et al. (2003). CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am J Pathol 162: 691-702.
15. Feng S, Ku K, Hodzic E, Lorenzana E, Freet K, Barthold SW. (2005). Differential detection of five mouse-infecting helicobacter species by multiplex PCR. Clin Diagn Lab Immunol 12: 531-536.
16. Forbs D, Thiel S, Stella MC, Sturzebecher A, Schweinitz A, Steinmetzer T et al. (2005). In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol 27: 1061-1070.
17. Garrett WS, Punit S, Gallini CA, Michaud M, Zhang D, Sigrist KS et al. (2009). Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell 16: 208-219.
18. Gaspar C, Cardoso J, Franken P, Molenaar L, Morreau H, Moslein G et al. (2008). Cross-species comparison of human and mouse intestinal polyps reveals conserved mechanisms in adenomatous polyposis coli (APC)-driven tumorigenesis. Am J Pathol 172: 1363-1380.
19. Hale LP, Perera D, Gottfried MR, Maggio-Price L, Srinivasan S, Marchuk D. (2007). Neonatal co-infection with helicobacter species markedly accelerates the development of inflammation-associated colonic neoplasia in IL-10(-/-) mice. Helicobacter 12: 598-604.
20. Hardwick JC, Kodach LL, Offerhaus GJ, van den Brink GR. (2008). Bone morphogenetic protein signalling in colorectal cancer. Nat Rev Cancer 8: 806-812.
21. Ihara S, Miyoshi E, Ko JH, Murata K, Nakahara S, Honke K et al. (2002). Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1-6 GlcNAc branching. J Biol Chem 277: 16960-16967.
22. Jin X, Yagi M, Akiyama N, Hirosaki T, Higashi S, Lin CY et al. (2006). Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci 97: 1327-1334.
23. Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jessen WJ et al. (2007). Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 8: R131.
24. Kaser A, Zeissig S, Blumberg RS. (2010). Inflammatory bowel disease. Annu Rev Immunol 28: 573-621.
25. Kessenbrock K, Plaks V, Werb Z. (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67.
26. Kilpatrick LM, Harris RL, Owen KA, Bass R, Ghorayeb C, Bar-Or A et al. (2006). Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. Blood 108: 2616-2623.
27. Kim MG, Chen C, Lyu MS, Cho EG, Park D, Kozak C et al. (1999). Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics 49: 420-428.
28. Lacy-Hulbert A, Smith AM, Tissire H, Barry M, Crowley D, Bronson RT et al. (2007). Ulcerative colitis and autoimmunity induced by loss of myeloid alphav integrins. Proc Natl Acad Sci USA 104: 15823-15828.
29. Lee SL, Dickson RB, Lin CY. (2000). Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 275: 36720-36725.
30. Lin CY, Anders J, Johnson M, Sang QA, Dickson RB. (1999). Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem 274: 18231-18236.
31. List K, Haudenschild CC, Szabo R, Chen W, Wahl SM, Swaim W et al. (2002). Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21: 3765-3779.
32. List K, Kosa P, Szabo R, Bey AL, Wang CB, Molinolo A et al. (2009). Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. Am J Pathol 175: 1453-1463.
33. List K, Szabo R, Molinolo A, Sriuranpong V, Redeye V, Murdock T et al. (2005). Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev 19: 1934-1950.
34. Lopez-Otin C, Matrisian LM. (2007). Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7: 800-808.
35. Lopez-Otin C, Palavalli LH, Samuels Y. (2009). Protective roles of matrix metalloproteinases: from mouse models to human cancer. Cell Cycle 8: 3657-3662.
36. Madison BB, Dunbar L, Qiao XT, Braunstein K, Braunstein E, Gumucio DL. (2002). Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J Biol Chem 277: 33275-33283.
37. Maggio-Price L, Treuting P, Zeng W, Tsang M, Bielefeldt-Ohmann H, Iritani BM. (2006). Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res 66: 828-838.
38. McCawley LJ, Crawford HC, King Jr LE, Mudgett J, Matrisian LM. (2004). A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res 64: 6965-6972.
39. McCawley LJ, Wright J, LaFleur BJ, Crawford HC, Matrisian LM. (2008). Keratinocyte expression of MMP3 enhances differentiation and prevents tumor establishment. Am J Pathol 173: 1528-1539.
40. Medema JP, Vermeulen L. (2011). Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature 474: 318-326.
41. Mohamed MM, Sloane BF. (2006). Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6: 764-775.
42. Netzel-Arnett S, Currie BM, Szabo R, Lin CY, Chen LM, Chai KX et al. (2006). Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J Biol Chem 281: 32941-32945.
43. Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH et al. (2003). Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 22: 237-258.
44. Newman JV, Kosaka T, Sheppard BJ, Fox JG, Schauer DB. (2001). Bacterial infection promotes colon tumorigenesis in Apc(Min/+) mice. J Infect Dis 184: 227-230.
45. Oberst MD,Williams CA, Dickson RB, Johnson MD, Lin CY. (2003). The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem 278: 26773-26779.
46. Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S. (1996). Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 39: 87-92.
47. Okayasu I, Yamada M, Mikami T, Yoshida T, Kanno J, Ohkusa T. (2002). Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J Gastroenterol Hepatol 17: 1078-1083.
48. Owen KA, Qiu D, Alves J, Schumacher AM, Kilpatrick LM, Li J et al. (2010). Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochem J 426: 219-228.
49. Palavalli LH, Prickett TD, Wunderlich JR, Wei X, Burrell AS, Porter-Gill P et al. (2009). Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet 41: 518-520.
50. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. (2004). Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118: 229-241.
51. Reinheckel T, Hagemann S, Dollwet-Mack S, Martinez E, Lohmuller T, Zlatkovic G et al. (2005). The lysosomal cysteine protease cathepsin L regulates keratinocyte proliferation by control of growth factor recycling. J Cell Sci 118: 3387-3395.
52. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6.
53. Riley LK, Franklin CL, Hook Jr RR, Besch-Williford C. (1996). Identification of murine helicobacters by PCR and restriction enzyme analyses. J Clin Microbiol 34: 942-946.
54. Rudolph U, Finegold MJ, Rich SS, Harriman GR, Srinivasan Y, Brabet P et al. (1995). Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice. Nat Genet 10: 143-150.
55. Saleh M, Trinchieri G. (2011). Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol 11: 9-20.
56. Sales KU, Masedunskas A, Bey AL, Rasmussen AL, Weigert R, List K et al. (2010). Matriptase initiates activation of epidermal prokallikrein and disease onset in a mouse model of Netherton syndrome. Nat Genet 42: 676-683.
57. Sandilands A, Sutherland C, Irvine AD, McLean WH. (2009). Filaggrin in the frontline: role in skin barrier function and disease. J Cell Sci 122: 1285-1294.
58. Schreiber S, Rosenstiel P, Albrecht M, Hampe J, Krawczak M. (2005). Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet 6: 376-388.
59. Shah SA, Simpson SJ, Brown LF, Comiskey M, de Jong YP, Allen D et al. (1998). Development of colonic adenocarcinomas in a mouse model of ulcerative colitis. Inflamm Bowel Dis 4: 196-202.
60. Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao Y et al. (2006). Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 38: 337-342.
61. Sternlicht MD, Bissell MJ, Werb Z. (2000). The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene 19: 1102-1113.
62. Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW et al. (1999). The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 98: 137-146.
63. Su L, Shen L, Clayburgh DR, Nalle SC, Sullivan EA, Meddings JB et al. (2009). Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 136: 551-563.
64. Suzuki M, Kobayashi H, Kanayama N, Saga Y, Lin CY, Dickson RB et al. (2004). Inhibition of tumor invasion by genomic downregulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem 279: 14899-14908.
65. Szabo R, Bugge TH. (2011). Membrane anchored serine proteases in cell and developmental biology. Annu Rev Cell Dev Biol 27: 213-235.
66. Szabo R, Rasmussen AL, Moyer AB, Kosa P, Schafer J, Molinolo A et al. (2011). c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene 30: 2003-2016.
67. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. (2000). Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 275: 26333-26342.
68. Takeuchi T, Shuman MA, Craik CS. (1999). Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 96: 11054-11061.
69. Tanimoto H, Underwood LJ, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ. (2001). Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol 22: 104-114.
70. Ustach CV, Huang W, Conley-LaComb MK, Lin CY, Che M, Abrams J et al. (2010). A novel signaling axis of matriptase/PDGFD/ss-PDGFR in human prostate cancer. Cancer Res 70: 9631-9640.
71. Van Limbergen J, Wilson DC, Satsangi J. (2009). The genetics of Crohn's disease. Annu Rev Genomics Hum Genet 10: 89-116.
72. Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S et al. (2002). Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295: 1726-1729.
73. Xavier RJ, Podolsky DK. (2007). Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434.
74. Zeki SS, Graham TA, Wright NA. (2011). Stem cells and their implications for colorectal cancer. Nat Rev Gastroenterol Hepatol 8: 90-100.
75. Zhang Y, Cai X, Schlegelberger B, Zheng S. (1998). Assignment1 of human putative tumor suppressor genes ST13 (alias SNC6) and ST14 (alias SNC19) to human chromosome bands 22q13 and 11q24-4q25 by in situ hybridization. Cytogenet Cell Genet 83: 56-57.